News

Australia's life science industry performed relatively well in the December 2011 quarter despite macroeconomic pressures, according to the PricewaterhousCoopers BioForum Report, with indicators good for the near future.

A new study found more than 1.2 million people died from malaria in 2010, although the disease is on the decline thanks to new treatments.

Global real-time collaboration and rapid access to vast data resources are spurring scientific innovation and discovery.

Starpharma Holdings (ASX:SPL) shares climbed 12.4% on Wednesday, after the release of positive results from a preclincial study of its dendrimer-docetaxel chemotherapy formulation.

The initial $3m Bionomics has received from its drug development deal with Ironwood Pharmaceuticals could help speed an improvement in cashflow.

The US National Science Advisory Board for Biosecurity has explained in detail its rationale in requesting two papers dealing with highly pathogenic H5N1.

Melbourne-based Immuron (ASX:IMC) and Monash University will collaborate on products aimed at treating C. difficile infections, using Immuron's colostrum technology.

Indian pharmaceutical company Strides Arcolab has sold its Australian generic pharmaceutical manufacturer Ascent Pharmahealth to Watson Pharmaceutical.

The US Food and Drug Administration has given the go-ahead for Mesoblast (ASX:MSB) to conduct phase II trials of its stem cell treatment for Type 2 diabetes.

The Prime Minister’s Prizes for Science are now open for nomination, including the $50,000 Science Minister’s Prize for Life Scientist of the Year.

The Monash Institute of Pharmaceutical Sciences and France's Servier have entered a three-year partnership for drug development research into G Protein-Coupled Receptors.

Researchers have found a drug that removes excess iron from the brain can prevent Parkinson’s and Alzheimer's disease in mice, raising the prospect of a new treatment.

Malcolm Simons, pioneer of so-called ‘junk’ DNA, has passed away, succumbing to multiple myeloma at the age of 73.

Brisbane-based biopharma Xenome Limited has secured $8m in funding from its major investors to pay for a clinical trial of a synthetic peptide as a pain inhibitor.

In this issue: Lorne 2012; the war on superbugs; microRNAs; streamlining drug development; stem cell therapy; and more.

Funds sought to take monoclonal antibody treatment for multiple cancers into phase I trials on the lead up to IND submission with the US Food and Drug Administration.

The discovery of new epigenetic markers present in a majority of ovarian cancers could lead to improved early diagnosis of the deadly disease.

After suffering two costly delays, BioProspect (ASX:BPO) is refocusing on gaining local regulatory approval for its lead animal health product.

Sienna Cancer Diagnostics has reached a new agreement with licensor Geron for the IP needed to continue development its telomerase protein detector tests.

Researchers at the Walter and Eliza Hall Institute have identified a molecule that helps the malaria virus hide from the immune system.